$BMY Recent News 4 stocks to watch 1:44 p.m. Nov. 19,

New Post Public Reply Private Reply Replies (0) Message Board

Dec 7, 2014 at 9:47 AM

$BMY Recent News

4 stocks to watch 1:44 p.m. Nov. 19, 2014 - The Trading Deck
77 stocks in the S&P 500 Index rise to new highs 10:50 a.m. Nov. 12, 2014 - Philip van Doorn
Charting a bullish post-election backdrop 11:05 a.m. Nov. 5, 2014 - Michael Ashbaugh
6 stocks to watch 1:35 p.m. Oct. 29, 2014 - The Trading Deck
Updates, advisories and surprises 11:31 a.m. Oct. 24, 2014 - MarketWatch
Amazon, Pandora sink in wake of results; KLA-Tencor surges 9:49 a.m. Oct. 24, 2014 - Sue Chang
Bristol-Myers profit slips, but tops expectations 6:45 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers sees 2014 total sales $15.2 bln-$15.8 bln vs. FactSet consensus $15.58 bln 6:35 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers lowers 2014 net EPS outlook to $1.15-$1.25 from $1.50-$1.60 6:35 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers affirms 2014 adj. EPS outlook of $1.70-$1.80 6:34 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 FactSet sales consensus $3.81 bln 6:33 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 sales $3.92 bln vs. $4.07 bln a year ago 6:33 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 adj. EPS 45 cents vs. FactSet consensus 42 cents 6:32 a.m. Oct. 24, 2014 - Tomi Kilgore
Mead Johnson Nutrition profit rises 9.5% 7:21 a.m. Oct. 23, 2014 - MarketWatch.com
More than 1/3 of Dow stocks to report this week 4:31 a.m. Oct. 19, 2014 - Wallace Witkowski
Bristol-Myers drops Hepatitis C dual regimen in U.S. 10:15 a.m. Oct. 7, 2014 - Jonathan D. Rockoff
FDA approves Merck's new-kind of cancer drug 1:58 p.m. Sept. 4, 2014 - MarketWatch.com
5 companies that will benefit from ALS awareness 6:58 a.m. Aug. 22, 2014 - Jennifer Booton
Glaxo chief faces increasing pressure: WSJ 5:29 p.m. Aug. 11, 2014 - MarketWatch.com
Bristol-Myers adjusted profit beats expectations 7:24 a.m. July 24, 2014 - MarketWatch.com

InsiderInsights.com Daily Round Up 12/5/14: HEES, CCC, CUDA, SC 3:27 a.m. Today - Seeking Alpha
Two Cancer Drugs Shown Effective 1:09 p.m. Dec. 6, 2014 - The Wall Street Journal Interactive Edition
Merck, Bristol Immunotherapies Expand Strongly Into Blood Cancers 1:00 p.m. Dec. 6, 2014 - TheStreet.com
Seattle Genetics Makes Case for Expanded Use of Adcetris as Lymphoma Maintenance Therapy 11:00 a.m. Dec. 6, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Google Is Better Than the Market Thinks 8:31 p.m. Dec. 4, 2014 - TheStreet.com
Can Albert Einstein's Math Get You To The Finish Line? Retirement Portfolio Quarterly Review 3:57 p.m. Dec. 4, 2014 - Seeking Alpha
Cancer’s Super-Survivors 1:46 p.m. Dec. 4, 2014 - The Wall Street Journal Interactive Edition
Cramer's Mad Money - PVH Fits Well At A Discount (12/3/14) 6:04 a.m. Dec. 4, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Cyclical Stocks Are Fund Manager Picks Now 8:36 p.m. Dec. 3, 2014 - TheStreet.com
Avanir Stock Jumps On $3.5 Billion Otsuka Buyout 10:22 a.m. Dec. 2, 2014 - Investors Business Daily
Retirement Portfolio For Dummies - The Health Care Components 1:42 p.m. Nov. 30, 2014 - Seeking Alpha
Vargatef cleared in Europe for lung cancer 9:23 a.m. Nov. 28, 2014 - Seeking Alpha
FDA Seeks More Data on Bristol-Myers Hepatitis C Therapy 12:17 p.m. Nov. 26, 2014 - The Wall Street Journal Interactive Edition
Bristol-Myers gets CRL for daclatasvir NDA 11:51 a.m. Nov. 26, 2014 - Seeking Alpha
December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey 6:00 a.m. Nov. 26, 2014 - TheStreet.com
Drug makers face pushback on pricey meds 8:18 a.m. Nov. 25, 2014 - Seeking Alpha
Bristol-Myers and Five Prime team up in cancer 9:29 a.m. Nov. 24, 2014 - Seeking Alpha
Pfizer/Merck KGaA Immune Checkpoint Deal Bodes Extremely Well For Compugen 12:21 p.m. Nov. 21, 2014 - Seeking Alpha
European Ad Comm gives thumbs up to AbbVie's HCV combo 8:48 a.m. Nov. 21, 2014 - Seeking Alpha
3 Best Vanguard Funds With Active Management 5:30 a.m. Nov. 21, 2014 - InvestorPlace.com

Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma 1:00 p.m. Dec. 6, 2014 - BusinessWire - BZX
A New Combined Approach to Cancer Immunotherapy is Needed 12:35 p.m. Dec. 1, 2014 - ACCESSWIRE
Bristol-Myers Squibb Foundation Marks World AIDS Day by Awarding $1.47 Millionin New Grants to Strengthen HIV-Related Services in Five Sub-Saharan Countries 9:01 a.m. Dec. 1, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Receives Complete Response Letter from U.S. Food and Drug Administration for Daclatasvir, an Investigational Treatment for Hepatitis C 11:34 a.m. Nov. 26, 2014 - BusinessWire - BZX
Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 8:24 p.m. Nov. 24, 2014 - PR Newswire - PRF
Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Types 8:59 a.m. Nov. 24, 2014 - BusinessWire - BZX
Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Types 8:59 a.m. Nov. 24, 2014 - GlobeNewswire
Analyses from Phase IIIb Study Provide Additional Data in Earlier Use of Orencia (abatacept) Plus Methotrexate (MTX) in Citrullinated Protein (CCP)-Positive Adult Patients with Early Rheumatoid Arthritis (RA) 8:03 a.m. Nov. 17, 2014 - BusinessWire - BZX
Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase 3 Trial 3:45 a.m. Nov. 16, 2014 - BusinessWire - BZX
Bristol-Myers Squibb to Present Sixteen Orencia (abatacept) Data Abstracts at The American College of Rheumatology (ACR) 2014 Annual Meeting 8:36 a.m. Nov. 12, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Foundation Awards $2 Million in New Grantsto Help Veterans and their Families Transition from Military to Civilian Life 9:00 a.m. Nov. 10, 2014 - BusinessWire - BZX
Upcoming Conferences, Contract Award, Quarterly Financial Results, and Completion of Acquisition - Research Reports on Bristol-Myers Squibb, 3M, Colony Financial, NOV and PPG 8:40 a.m. Nov. 10, 2014 - PR Newswire - PRF
ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients 9:00 a.m. Nov. 8, 2014 - BusinessWire - BZX
Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis 9:00 a.m. Nov. 8, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Receives the LEAD Award from The US Oncology Network 10:33 a.m. Nov. 7, 2014 - BusinessWire - BZX
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries 8:50 a.m. Nov. 6, 2014 - PR Newswire - PRF
Protagonist Therapeutics Elects Chaitan Khosla, Ph.D. to Board of Directors 8:35 a.m. Nov. 5, 2014 - PR Newswire - PRF
Lexicon Strengthens Clincial Operations And Commercial Readiness 4:15 p.m. Nov. 4, 2014 - PR Newswire - PRF
Bristol-Myers Squibb to Present at Credit Suisse 2014 Health Care Conference 10:00 a.m. Nov. 4, 2014 - BusinessWire - BZX
Insider Trading Research for Micron, Bristol-Myers Squibb, Twitter, American Realty Capital Properties, Plug Power, and GoPro 8:45 a.m. Nov. 3, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EQS Group Unveils 'Q': AI-Driven Compliance Revolution

Compliance in the Fast Lane The compliance world just got a hefty upgrade with EQS Group's latest rollout: 'Q by EQS,' an AI-powered intelligence layer that's here to shake up the way compliance tasks are handled. It's integrated right into the heart of the EQS Compliance Cockpit, giving teams an edge by automating those pesky, time-sucking routines and guiding them...

GeneDx Faces Scrutiny: Are Fiduciary Duties at Risk?

What's Brewing at GeneDx? Looks like GeneDx Holdings Corp. is in some hot water—at least that's what Halper Sadeh LLC seems to think. Not your regular Tuesday at the exchange, folks. This legal eagle outfit is poking around GeneDx's henhouse, signaling possible breaches of fiduciary duties by their officers and directors. It's like catching a whiff of something fishy...

Microplastics Found in Human Blood: Alarming Evidence

An Unsettling Discovery in Our Veins Microplastics in the blood? Yep, you read that right, and it’s not some sci-fi horror story—it’s today’s harsh reality. A riveting report from the likes of the Plastic Pollution Coalition and the Canadian Association of Physicians for the Environment has thrown a bucket of cold water on us. They uncovered microplastics in 96%...

LabWare Loop: A Game Changer for Lab Data Integrity

Breaking Down Silos in Lab Environments When it comes to the controlled chaos of laboratory operations, data integrity is the name of the game. We're talking about a new way of doing things that doesn't demand a physics degree just to connect the dots between gizmos and databases. Enter LabWare Loop, a solution that's rewriting the data playbook by linking multi-vendor...

Lennox Faces Pressures Amidst Strong Revenue Growth

Revenue Surge but Margin Squeeze Out there in the land of HVAC, Lennox International (NYSE: LII) just dropped its third quarter earnings for 2026. Sure, they raked in a solid $1.6 billion—up a hearty 10%. But all that glitters ain't gold, and the company's operating income took a hit down to $312 million, shedding a cool five percent from last year. Challenges Weighing...

Raleigh's Auction Direct Stresses Oil Changes

Keeping Engines Humming in Raleigh There's nothing quite like keeping an engine running like clockwork, especially in a place like Raleigh where folks rely on their rides day in and day out. That's where Auction Direct USA steps in, offering professional oil change services aimed at preserving the performance and reliability of used cars. A simple yet crucial service:...

Corgi Insurance Eyes $100B Auto Market with New Launch

Leaping Into a Booming Market Well, it looks like someone lit a fire under Corgi Insurance, and they're ready to chase bigger bones. They’ve just rolled out a product called Corgi Business Auto, signaling quite a bold move into the hefty, nearly $100 billion U.S. commercial auto insurance arena. Now, as an old hand at this game, my ears perk up whenever I see a player...

Auction Direct USA Offers Budget-Friendly Used Cars

Dollars and Sense: Affordable Cars in Raleigh Listen up, folks. These days, unless you're on the hunt for a fancy ride decked out with every bell and whistle, the idea of nabbing a car under ten grand almost sounds like a fairytale. But Auction Direct USA in Raleigh is making this dream a reality. That’s right, a whole fleet of used cars, all priced under $10,000, is...

AvePoint Joins S&P SmallCap 600, Replacing LXP

Shifting Scenes in the SmallCap Index Wall Street always throws a curveball right when you think you've seen it all. This time, it's AvePoint Inc. (NASD: AVPT) making waves as it steps into the S&P SmallCap 600 ring come November 2. Booting out LXP Industrial Trust (NYSE: LXP), this whole shuffle's coming down because those guys over at Brookfield Asset Management Ltd....

Photocure's Q3 2026: Revenue Plateau and CFO Shakeup

The Bladder Cancer Scene: Steady as She Goes Sometimes, you look at numbers and find tranquility, like staring into still waters. That's the scene over at Photocure ASA with their latest Q3 results. Clocking in with revenues of NOK 134.2 million from their Hexvix®/Cysview® products, they're barely flinching from last year's NOK 134.1 million. Is it a victory or a...